IP Library Granted Patent US 10,406,181
Granted Patent B2
US 10,406,181 · App. 15/791,638 · Granted Sep 10, 2019

Method for reducing the inflammatory activity of a stem cell transplant and use thereof

Inventors: Johannes Petrus Jozef Maria De Munter (Banholt, NL); Ekkehard Lang (Weinbach, DE); Erik Charles Marie Joseph Wolters (Amsterdam, NL); Petrus Theodorus De Haan (Oegstgeest, NL)
Assignee: Neuroplast Beheer B.V.
A61K35/28A01K67/0271A61K35/16A61K38/1722C12N5/0087C12N5/0647C12N5/0663A01K2207/30A01K2227/105A01K2267/0356A01K2267/0368A61K2035/124C12N2533/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,406,181
App. No.
15/791,638
Granted
Sep 10, 2019
Kind
B2
Abstract

The disclosure is in the field of cell therapy, more in particular, stem cell transplantation therapy. The disclosure provides methods and compositions for improving the efficacy of stem cell transplantation therapy by reducing the inflammatory activity of a stem cell transplant. More in particular, the disclosure provides a method for preparing a stem cell transplant with reduced inflammatory activity comprising a step of suspending a composition comprising stem cells in a fibrinogen-depleted plasma and/or in a fibrinogen and C-reactive protein-depleted plasma.

Claims (7)

1. A composition comprising (i) a hematopoietic stem cell and (ii) plasma or serum, wherein the plasma or serum is depleted of fibrinogen and C-reactive protein.

2. The composition of claim 1 , wherein, additionally, the composition is depleted of pro-inflammatory cells.

3. The composition of claim 1 , wherein the hematopoietic stem cell is a human hematopoietic stem cell.

4. A method of treating a subject to induce tissue regeneration in a subject in need thereof, wherein the tissue regeneration is selected from the group consisting of neural, vascular and hematopoietic tissue regeneration, comprising administering to the subject a therapeutically effective amount of the composition of claim 1 .

5. The method according to claim 4 , wherein the tissue regeneration is a therapy for spinal cord injury.

6. The method according to claim 4 , wherein the stem cell is autologous.

7. The method of claim 6 , wherein the treatment is autologous transplantation therapy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2018
From: DE MUNTER, JOHANNES PETRUS JOZEF MARIA; LANG, EKKEHARD; WOLTERS, ERIK CHARLES MARIE JOSEPH; DE HAAN, PETRUS THEODORUS
To: NEUROPLAST BEHEER B.V.
Reel/Frame 045301/0347 →
Priority Claims (1)
EP 13190120 · Oct 24, 2013 · regional
Continuity (2)
Division 15029206
Related Publication 20180042967A1 · Feb 15, 2018